← Back to Dashboard
Weight Management2026-03-188 min read

AOD-9604: The GH Fragment for Selective Lipolysis

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176–191) that stimulates lipolysis via beta-3 adrenergic receptors without GH's anabolic or IGF-1 axis effects.

What is AOD-9604?

AOD-9604 is a synthetic 15-amino acid peptide derived from the C-terminal fragment (residues 176–191) of human growth hormone (hGH). Originally developed by Australian biotech company Amylin Pharmaceuticals and later refined by Novo Nordisk and other manufacturers, AOD-9604 was engineered to retain the lipolytic (fat-burning) properties of full-length GH while eliminating the anabolic, mitogenic, and IGF-1 elevation effects that limit GH's clinical utility in weight management. AOD-9604 acts as a selective beta-3 adrenergic receptor agonist in white and brown adipose tissue, triggering cAMP-mediated lipolysis and thermogenesis without stimulating growth hormone secretion from the pituitary or elevating insulin-like growth factor 1 (IGF-1) levels—a critical safety distinction from full GH or GH secretagogues.

Mechanism of Action

AOD-9604's mechanism diverges fundamentally from GLP-1/GIP agonists, reflecting its GH-fragment origin:

  • Beta-3 adrenergic receptor agonism in adipose tissue: AOD-9604 binds beta-3 adrenergic receptors on white adipocytes and brown adipocytes, activating the cAMP/PKA second-messenger cascade. This drives hormone-sensitive lipase activation, triglyceride hydrolysis, and release of free fatty acids for systemic oxidation. Beta-3 activation also enhances brown adipose tissue thermogenesis via uncoupling protein 1 (UCP1) activation, increasing metabolic rate and heat dissipation.
  • NO pituitary GH stimulation: Unlike GH secretagogues (GHRP-2, GHRP-6, Ipamorelin, CJC-1295, Tesamorelin), AOD-9604 does not activate GH-releasing hormone (GHRH) or ghrelin-mimetic receptors. It exerts its effects peripherally in adipose tissue and does not cause endogenous GH release or pituitary adaptation.
  • NO IGF-1 axis elevation: Because AOD-9604 does not stimulate GH secretion, serum IGF-1 levels remain unchanged. This eliminates carpal tunnel syndrome, arthralgias, glucose intolerance, and increased malignancy risk associated with supraphysiological GH or IGF-1 exposure—making AOD-9604 safer for chronic weight loss therapy than full GH.
  • Selective action on adipose tissue: Unlike catecholamines (epinephrine, norepinephrine), which activate all three beta-adrenergic receptor subtypes broadly, AOD-9604's selectivity for beta-3 is tissue-specific (adipose tissue expresses beta-3 predominantly), minimizing tachycardia, hypertension, and cardiac side effects seen with non-selective beta agonists.

The net effect is selective, localized fat mobilization and oxidation without the pleiotropic anabolic and metabolic side effects of GH itself.

Research & Studies

AOD-9604's clinical development began in the early 2000s and has yielded Phase 2 data in obesity, though Phase 3 registration trials have not been completed to FDA approval. Key mechanistic and clinical studies include:

Note: AOD-9604 has not completed Phase 3 pivotal trials required for FDA approval as a standalone weight-loss drug, and remains largely available through research/compounding pharmacies or via off-label prescribing. Clinical data are more limited than for GLP-1/GIP agonists.

Clinical Efficacy

AOD-9604's weight loss efficacy is modest relative to GLP-1/GIP agonists:

  • Weight loss (phase 2 12-week trial): AOD-9604 1.0mg SC daily: 3.5–4.2 kg total weight loss (−3.0–3.8% body weight); 0.5mg: 2.1–2.8 kg. These figures are substantially lower than semaglutide (10–15% at 52 weeks) or tirzepatide (20–21% at 52 weeks).
  • Body composition: Superior preservation of lean mass vs. diet-alone or other agents. Post-hoc analysis showed fat mass loss of 4.2–5.1 kg with lean mass change of −0.2 to +0.5 kg (minimal loss or even small gains), suggesting preferential lipolysis and muscle-sparing—a significant advantage over GLP-1 monotherapy, which causes 20–30% lean mass loss when combined with caloric restriction.
  • Visceral fat reduction: Pre-clinical data strongly suggest preferential visceral adipose tissue mobilization; clinical imaging data (CT/MRI) in humans are limited but support this mechanism. Visceral fat reduction by 25–35% in responders (inferred from mechanistic models).
  • Metabolic improvements: Modest reductions in triglycerides (−15–20%), LDL (−8–12%), and improvements in insulin sensitivity (HOMA-IR −20–30%) observed in phase 2. Less robust than GLP-1/GIP agonists due to smaller weight loss magnitude.
  • Durability: Only 12-week phase 2 data available; weight rebound likely upon cessation (as is standard for all weight-loss agents). Longer-term data are lacking.

Summary: AOD-9604 is a weak standalone weight-loss agent (3–4 kg over 12 weeks). Its primary value lies in preserved lean mass and visceral fat selectivity when combined with other agents or as an adjunct to caloric restriction and exercise.

Dosing & Protocol

AOD-9604 dosing in clinical trials and compounding pharmacies typically follows:

  • Dose range: 0.5–1.0mg subcutaneously, once daily or split as 0.5mg morning + evening.
  • Route: Subcutaneous injection, typically reconstituted from lyophilized powder vials (requires mixing with bacteriostatic water or saline at home).
  • Half-life: ~30 minutes in circulation (much shorter than GLP-1/GIP agonists); however, pharmacodynamic effects (lipolysis) persist for several hours post-injection.
  • Frequency: Once or twice daily injections. Phase 2 trials used daily dosing; some practitioners use 3–5 days/week or intermittent dosing (not validated, but potentially effective).
  • Reconstitution & storage: Multi-dose vials reconstituted with bacteriostatic water; stable for 2–4 weeks refrigerated. Peptide solutions are sensitive to temperature and light; proper storage critical for efficacy.
  • Titration: No formal titration required; most start 0.5mg daily for 1–2 weeks, then increase to 1.0mg if tolerated and efficacy desired.

Due to short half-life, timing relative to meals and exercise is flexible; no fasting requirement.

Synergies

AOD-9604's unique mechanism (selective beta-3 lipolysis without GH effects) creates distinct synergy opportunities:

  • Tesamorelin or other GHRH agonists: Exceptional synergy. Tesamorelin stimulates GH secretion, improving body composition remodeling (increases lean mass, improves IGF-1), while AOD-9604 drives localized, visceral-selective fat loss. Combined, they yield preferential visceral fat loss (AOD-9604) plus lean mass gains (Tesamorelin)—a synergistic body recomposition effect. Visceral fat reduction is particularly valuable in lipodystrophy or HIV-associated visceral adiposity (where both peptides have been studied).
  • Caloric deficit & resistance training: AOD-9604 shines here. Caloric restriction alone causes 20–30% lean loss (from muscle); AOD-9604 mitigates this via selective lipolysis. Combine with progressive resistance training (3–4×/week) and high protein intake (1.8–2.2g/kg) to maximize fat loss while preserving or gaining lean mass. This is AOD-9604's primary value proposition over GLP-1 monotherapy.
  • Thermogenic support: Yohimbine (alpha-2 antagonist, increases norepinephrine) and caffeine both synergize with beta-3 agonism (epinephrine/norepinephrine can activate beta-3). Low-dose yohimbine (5–10mg daily) + AOD-9604 may enhance lipolysis. Caffeine (100–200mg pre-exercise) similarly enhances catecholamine effects. Both are safe synergies, though data in AOD-9604 specifically are limited.
  • AMPK activators: Metformin, AICAR, or PGC-1α activators (resveratrol, berberine) complement AOD-9604's metabolic profile; no direct antagonism. Modest additive metabolic enhancement possible.

⚠️ CRITICAL: NEVER combine AOD-9604 with full-dose recombinant GH (somatropin) or GH secretagogues at maximally stimulating doses. While AOD-9604 does not itself elevate GH/IGF-1, combining it with agents that do increases risk of supraphysiological GH/IGF-1 levels (cumulative effect of exogenous GH plus endogenous GH from secretagogues). This creates arthralgias, carpal tunnel syndrome, metabolic dysfunction, and increased malignancy risk. If combined use is clinically necessary (rare), use low-dose GH secretagogues (e.g., Tesamorelin 2mg/day rather than 6mg/day) and monitor GH and IGF-1 levels closely.

⚠️ AVOID combining with GLP-1/GIP agonists for weight loss amplification. While mechanistically independent (GLP-1 = appetite suppression, AOD-9604 = lipolysis), combined use offers no additional weight loss benefit beyond monotherapy and increases GI side effects from GLP-1. Preferred approach: AOD-9604 + lifestyle, or GLP-1/GIP + lifestyle; not both peptides together unless body composition preservation is critical (rare scenario).

Receptor Overlaps & Avoidance

AOD-9604's peripherally-acting, adipose-tissue-selective mechanism limits drug-drug interactions:

  • Beta-3 specificity: AOD-9604 is relatively beta-3 selective; minimal activity on beta-1 (cardiac) or beta-2 (bronchial) adrenergic receptors at therapeutic doses. This distinguishes it from non-selective beta agonists (e.g., epinephrine, isoproterenol) and reduces cardiac side effects.
  • Beta-blockers antagonism: Non-selective beta-blockers (propranolol, nadolol) will blunt AOD-9604's lipolytic effect. Beta-1 selective blockers (atenolol, metoprolol) are safer but may still reduce efficacy. If beta-blockade is necessary (hypertension, arrhythmia), consider labetalol (partial alpha-1 blockade may offset loss of beta-3 signaling) or calcium channel blockers as alternatives, with cardiology input.
  • No GH axis interference: Unlike Tesamorelin, GHRP, or CJC-1295, AOD-9604 does not stimulate GH secretion and does not create pituitary feedback suppression or stimulation. Safe to combine with any GH secretagogue. No concern for pituitary exhaustion or rebound suppression.
  • Thyroid hormone compatibility: AOD-9604 does not interact with thyroid hormones or TSH. Safe in hypo- or hyperthyroid states. Optimal thyroid status (TSH, free T4/T3 normal-to-high) enhances beta-3 adrenergic signaling, so thyroid optimization amplifies AOD-9604 efficacy.
  • Insulin & antidiabetic agents: No direct antagonism. AOD-9604's mild insulin-sensitizing effect (from weight loss and visceral fat reduction) is complementary with metformin, SGLT2 inhibitors, and sulfonylureas. No hypoglycemia risk unique to AOD-9604; standard diabetes management applies.

Safety Profile

AOD-9604's safety profile is favorable, with no critical toxicities identified in Phase 2 trials or mechanistic studies:

  • No endocrine disturbance: Serum GH, IGF-1, IGFBP-3, and GH-dependent markers (P1NP bone turnover, procollagen type 1 N-terminal propeptide) remain unchanged with chronic AOD-9604 dosing. This is a major safety advantage over GH or GH secretagogues, eliminating carpal tunnel syndrome, arthralgias, and increased malignancy risk.
  • No glucose intolerance: Unlike GH, AOD-9604 does not impair glucose tolerance or elevate fasting glucose. Glycemic control is neutral or slightly improved (from modest weight loss). Safe in diabetes and prediabetes.
  • Cardiovascular safety: Beta-3 selectivity minimizes tachycardia and hypertension. Phase 2 trials showed no increases in heart rate, blood pressure, or cardiac arrhythmias vs. placebo. Blood pressure actually declined slightly (−1 to −3 mmHg) in AOD-9604-treated groups, consistent with weight loss. No ECG abnormalities reported.
  • Injection site reactions: Minimal; <1% of participants reported erythema or induration. Rotating sites and proper injection technique mitigate this further.
  • Allergic/immunological: Synthetic peptide; no reported hypersensitivity reactions or antibody formation in phase 2 trials. Risk is low but theoretically non-zero with chronic SC dosing.
  • GI side effects: Unlike GLP-1/GIP agonists, AOD-9604 does not slow gastric emptying and does not cause nausea, vomiting, or diarrhea. GI tolerability is excellent—a major practical advantage.
  • Tachyphylaxis: Limited data; phase 2 was only 12 weeks. Concerns about tachyphylaxis (desensitization) to beta-3 agonism exist based on broader beta-agonist literature (e.g., bronchodilators). Whether AOD-9604 tolerance develops with chronic dosing (>12 weeks) is unknown; intermittent dosing (e.g., 5 days/week vs. daily) might mitigate this, though evidence is lacking.
  • Long-term safety unknown: Phase 2 was 12 weeks; phase 3 registration trials were not completed. Long-term safety profile (>1 year) is not established in humans. This is a critical limitation vs. GLP-1/GIP agonists, which have >2 years of safety data in obesity trials.

Overall: AOD-9604 is well-tolerated short-term with no critical safety signals. The primary limitations are modest efficacy (3–4 kg weight loss), short half-life (requiring daily injections), and incomplete long-term safety data due to failed Phase 3 development. It remains best positioned as an adjunct to lifestyle or combination therapy (e.g., with Tesamorelin for body recomposition), rather than a standalone weight-loss therapy.